Your browser has javascript turned off or blocked. This will lead to some parts of our website to not work properly or at all. Turn on javascript for best performance.

The browser you are using is not supported by this website. All versions of Internet Explorer are no longer supported, either by us or Microsoft (read more here: https://www.microsoft.com/en-us/microsoft-365/windows/end-of-ie-support).

Please use a modern browser to fully experience our website, such as the newest versions of Edge, Chrome, Firefox or Safari etc.

Paul Franks

Paul Franks

Principal investigator

Paul Franks

Processes Underlying Glycemic Deterioration in Type 2 Diabetes : An IMI DIRECT Study

Author

  • Roberto Bizzotto
  • Christopher Jennison
  • Angus G. Jones
  • Azra Kurbasic
  • Andrea Tura
  • Gwen Kennedy
  • Jimmy D. Bell
  • E. Louise Thomas
  • Gary Frost
  • Rebeca Eriksen
  • Robert W. Koivula
  • Soren Brage
  • Jane Kaye
  • Andrew T. Hattersley
  • Alison Heggie
  • Donna McEvoy
  • Leen M. 't Hart
  • Joline W. Beulens
  • Petra Elders
  • Petra B. Musholt
  • Martin Ridderstråle
  • Tue H. Hansen
  • Kristine H. Allin
  • Torben Hansen
  • Henrik Vestergaard
  • Agnete T. Lundgaard
  • Henrik S. Thomsen
  • Federico De Masi
  • Konstantinos D. Tsirigos
  • Søren Brunak
  • Ana Viñuela
  • Anubha Mahajan
  • Timothy J. McDonald
  • Tarja Kokkola
  • Ian M. Forgie
  • Giuseppe N. Giordano
  • Imre Pavo
  • Hartmut Ruetten
  • Emmanouil Dermitzakis
  • Mark I. McCarthy
  • Oluf Pedersen
  • Jochen M. Schwenk
  • Jerzy Adamski
  • Paul W. Franks
  • Mark Walker
  • Ewan R. Pearson
  • Andrea Mari

Summary, in English

OBJECTIVE: We investigated the processes underlying glycemic deterioration in type 2 diabetes (T2D). RESEARCH DESIGN AND METHODS: A total of 732 recently diagnosed patients with T2D from the Innovative Medicines Initiative Diabetes Research on Patient Stratification (IMI DIRECT) study were extensively phenotyped over 3 years, including measures of insulin sensitivity (OGIS), β-cell glucose sensitivity (GS), and insulin clearance (CLIm) from mixed meal tests, liver enzymes, lipid profiles, and baseline regional fat from MRI. The associations between the longitudinal metabolic patterns and HbA1c deterioration, adjusted for changes in BMI and in diabetes medications, were assessed via stepwise multivariable linear and logistic regression. RESULTS: Faster HbA1c progression was independently associated with faster deterioration of OGIS and GS and increasing CLIm; visceral or liver fat, HDL-cholesterol, and triglycerides had further independent, though weaker, roles (R2 = 0.38). A subgroup of patients with a markedly higher progression rate (fast progressors) was clearly distinguishable considering these variables only (discrimination capacity from area under the receiver operating characteristic = 0.94). The proportion of fast progressors was reduced from 56% to 8-10% in subgroups in which only one trait among OGIS, GS, and CLIm was relatively stable (odds ratios 0.07-0.09). T2D polygenic risk score and baseline pancreatic fat, glucagon-like peptide 1, glucagon, diet, and physical activity did not show an independent role. CONCLUSIONS: Deteriorating insulin sensitivity and β-cell function, increasing insulin clearance, high visceral or liver fat, and worsening of the lipid profile are the crucial factors mediating glycemic deterioration of patients with T2D in the initial phase of the disease. Stabilization of a single trait among insulin sensitivity, β-cell function, and insulin clearance may be relevant to prevent progression.

Department/s

  • Genetic and Molecular Epidemiology
  • EpiHealth: Epidemiology for Health
  • EXODIAB: Excellence in Diabetes Research in Sweden

Publishing year

2021

Language

English

Pages

511-518

Publication/Series

Diabetes Care

Volume

44

Issue

2

Document type

Journal article

Publisher

American Diabetes Association

Topic

  • Endocrinology and Diabetes

Status

Published

Research group

  • Genetic and Molecular Epidemiology

ISBN/ISSN/Other

  • ISSN: 1935-5548